Drug recall · December 19, 2018
Amlodipine and Valsartan Tablets recall
Why: CGMP Deviations: FDA lab confirmed presence an impurity, N-nitrosodiethylamine (NDEA) contained in the API used to manufacture the product.
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
Amlodipine and Valsartan Tablets, USP, 5 mg/160 mg, 30-count bottle, Rx Only, Made in India, Manufactured for: Mylan Pharmaceuticals, Inc., Morgantown, WV 26505, U.S.A., NDC 0378-1721-93.
- Lots / codes
Lot # 3066051, exp. date 3/2019
- Quantity
- 23,478 bottles
- Company
- Mylan Pharmaceuticals Inc., Morgantown, WV
- Distribution
- Product was distributed throughout the United States.
- Initiated
- November 20, 2018 · Voluntary: Firm initiated
- Classified
- December 14, 2018
- Reported
- December 19, 2018
- How notified
- Press Release
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Recalled with it (same recall event)
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Amlodipine / valsartan
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.